Skip to content
Triangle logo TriangleGet started
← Multiple Myeloma

NCT00075829 · STUDY IN CONTEXT

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Patients are considered a failure for this endpoint if they die or if they progress or relapse.

Patients that completed second transplant

→

secondary · POSTED

The event is death from any cause, patients alive at the time of last observation are considered censored.

Patients that completed second transplant

→

secondary · POSTED

The event is death from any cause, patients alive at the time of last observation are considered censored.

Patients that completed second transplant

→

secondary · POSTED

Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.

Patients that completed second transplant

→

secondary · POSTED

TRM is defined as death occurring in a patient from causes other than relapse or progression.

Patients that completed second transplant

→

secondary · POSTED

Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.

Patients that completed second transplant

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-multiple-myeloma
nct id
NCT00075829
trial label
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
4
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0000
    source section id
    NCT00075829-om-0000
    source outcome index
    0
    endpoint
    Progression-Free Survival (PFS)
    endpoint definition
    Patients are considered a failure for this endpoint if they die or if they progress or relapse.
    time origin
    Year 3
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0001
    source section id
    NCT00075829-om-0001
    source outcome index
    1
    endpoint
    Overall Survival (OS) for Standard Risk
    endpoint definition
    The event is death from any cause, patients alive at the time of last observation are considered censored.
    time origin
    Years 1, 2, and 3
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0002
    source section id
    NCT00075829-om-0002
    source outcome index
    2
    endpoint
    Overall Survival (OS) for High Risk
    endpoint definition
    The event is death from any cause, patients alive at the time of last observation are considered censored.
    time origin
    Year 3
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0003
    source section id
    NCT00075829-om-0003
    source outcome index
    3
    endpoint
    Cumulative Incidence of Progression/Relapse
    endpoint definition
    Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.
    time origin
    Year 3
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0004
    source section id
    NCT00075829-om-0004
    source outcome index
    4
    endpoint
    Cumulative Incidence of Treatment Related Mortality (TRM)
    endpoint definition
    TRM is defined as death occurring in a patient from causes other than relapse or progression.
    time origin
    Year 3
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0005
    source section id
    NCT00075829-om-0005
    source outcome index
    5
    endpoint
    Interval From First to Second Transplantation
    endpoint definition
    Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.
    time origin
    Year 1
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Patients that completed second transplant
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Auto-Auto Standard Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
    analyzed count
    366
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Auto-Allo Standard Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    analyzed count
    156
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0000
    arm key
    OG002
    arm label
    Auto-Auto High Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0000#groups/OG002
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0000
    arm key
    OG003
    arm label
    Auto-Allo High Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0000#groups/OG003
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Auto-Auto Standard Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
    analyzed count
    366
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0001#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Auto-Allo Standard Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    analyzed count
    156
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0001#groups/OG001
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Auto-Auto High Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0002#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Auto-Allo High Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0002#groups/OG001
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Auto-Auto Standard Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
    analyzed count
    366
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0003#groups/OG000
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0003
    arm key
    OG001
    arm label
    Auto-Allo Standard Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
    analyzed count
    156
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0003#groups/OG001
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0003
    arm key
    OG002
    arm label
    Auto-Auto High Risk
    regimen
    Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0003#groups/OG002
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    outcome key
    om-0003
    arm key
    OG003
    arm label
    Auto-Allo High Risk
    regimen
    Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00075829-om-0003#groups/OG003
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    harm key
    EG000
    source section id
    NCT00075829-ae
    event group key
    EG000
    event group label
    Auto-Auto Standard Risk
    serious affected
    15
    serious at risk
    436
    other affected
    1
    other at risk
    436
    frequency threshold
    .2
    collection period
    3-years post-first transplant
    event definition
    Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events were required to be reported through the adverse event system per protocol.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    harm key
    EG001
    source section id
    NCT00075829-ae
    event group key
    EG001
    event group label
    Auto-Allo Standard Risk
    serious affected
    10
    serious at risk
    189
    other affected
    1
    other at risk
    189
    frequency threshold
    .2
    collection period
    3-years post-first transplant
    event definition
    Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events were required to be reported through the adverse event system per protocol.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    harm key
    EG002
    source section id
    NCT00075829-ae
    event group key
    EG002
    event group label
    Auto-Auto High Risk
    serious affected
    2
    serious at risk
    48
    other affected
    0
    other at risk
    48
    frequency threshold
    .2
    collection period
    3-years post-first transplant
    event definition
    Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events were required to be reported through the adverse event system per protocol.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00075829
    harm key
    EG003
    source section id
    NCT00075829-ae
    event group key
    EG003
    event group label
    Auto-Allo High Risk
    serious affected
    5
    serious at risk
    37
    other affected
    0
    other at risk
    37
    frequency threshold
    .2
    collection period
    3-years post-first transplant
    event definition
    Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events were required to be reported through the adverse event system per protocol.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice